Zealand Pharma A/S (ZEAL) Stock Price, News & Analysis

Company Overview

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company markets lixisenatide under the brand names of Adlyxin and Lyxumia; Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia, congenital hyperinsulinism, and post bariatric surgery hypoglycemia; and Dasiglucagon dual-hormone artificial pancreas for automated diabetes management. The company's pipeline includes Dasiglucagon that is in Phase III clinical trials for congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; Alexion Pharmaceuticals, Inc.; and Beta Bionics, Inc. The company was incorporated in 1998 and is headquartered in Copenhagen, Denmark.

Key Stats

• Today's Range: $17.59 to $17.59
• 50-Day Range: $16.54 to $19.20
• 52-Week Range: $9.93 to $32.94
• Volume: N/A
• Average Volume: 4,965 shs
• Market Capitalization: $818.60 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ZEAL Stock Analysis - Frequently Asked Questions

How were Zealand Pharma A/S's earnings last quarter?

Zealand Pharma A/S (NASDAQ:ZEAL) released its earnings results on Wednesday, November, 10th. The company reported ($4.61) earnings per share for the quarter, topping the consensus estimate of ($6.31) by $1.70. The firm earned $16.87 million during the quarter, compared to analysts' expectations of $12.21 million. Zealand Pharma A/S had a negative trailing twelve-month return on equity of 111.04% and a negative net margin of 565.44%.

When did Zealand Pharma A/S IPO?

Zealand Pharma A/S (ZEAL) raised $75 million in an initial public offering (IPO) on Wednesday, August 9th 2017. The company issued 3,900,000 shares at a price of $19.30 per share. Morgan Stanley and Goldman Sachs served as the underwriters for the IPO and Guggenheim Securities and Needham & Company were co-managers.

What other stocks do shareholders of Zealand Pharma A/S own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Zealand Pharma A/S investors own include Sorrento Therapeutics (SRNE), NVIDIA (NVDA), Vertex Pharmaceuticals (VRTX), Editas Medicine (EDIT), Spectrum Pharmaceuticals (SPPI), AbbVie (ABBV) and CRISPR Therapeutics (CRSP).

Company Calendar

• Last Earnings: 11/10/2021
• Today: 6/15/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:ZEAL
• CIK: 1674988
• Web: www.zealandpharma.com
• Phone: (458) 877-3600
• Fax: 45-8877-3898
• Employees: 355
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($4.09)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$161.99 million
• Net Margins: -565.44%
• Pretax Margin: -364.34%
• Return on Equity: -111.04%
• Return on Assets: -56.54%

Debt

• Debt-to-Equity Ratio: 0.93
• Current Ratio: 4.79
• Quick Ratio: 4.78

Sales & Book Value

• Annual Sales: $46.54 million
• Price / Sales: 17.59
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.38 per share
• Price / Book: 5.20

Miscellaneous

• Outstanding Shares: 46,538,000
• Free Float: 45,514,000
• Market Cap: $818.60 million
• Optionable: Not Optionable
• Beta: 1.45